1. Hosseinpanah F, Kasraei F, Nassiri AA, Azizi F. High prevalence of chronic kidney disease in Iran: a large population-based study.
BMC Public Health 2009;9:44.
2. Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA. Chronic kidney disease and cardiovascular disease in the medicare population: management of comorbidities in kidney disease in the 21st century: anemia and bone disease.
Kidney Int 2003;64(Suppl 87):S24–S31.
3. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes.
Kidney Int 2007;72:247–259.
4. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population.
JAMA 2004;291:844–850.
5. Oh SH, Kim HY, Oak CY, et al. Prevalence and factors of chronic kidney disease. Korean J Nephrol 2010;29:441–449.
6. Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland.
J Am Soc Nephrol 2003;14:2934–2941.
7. Pirkle JL, Freedman BI. Hypertension and chronic kidney disease: controversies in pathogenesis and treatment.
Minerva Urol Nefrol 2013;65:37–50.
8. Drexler YR, Bomback AS. Definition, identification and treatment of resistant hypertension in chronic kidney disease patients.
Nephrol Dial Transplant 2014;29:1327–1335.
9. Norris KC, Nicholas SB. Strategies for controlling blood pressure and reducing cardiovascular disease risk in patients with chronic kidney disease.
Ethn Dis 2015;25:515–520.
10. International Society for Chronobiology; American Association of Medical Chronobiology and Chronotherapeutics; Spanish Society of Applied Chronobiology, Chronotherapy, and Vascular Risk, et al. 2013 Ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals.
Chronobiol Int 2013;30:355–410.
11. Pogue V, Rahman M, Lipkowitz M, et al. African American Study of Kidney Disease and Hypertension Collaborative Research Group. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease.
Hypertension 2009;53:20–27.
12. Godwin M, Birtwhistle R, Delva D, et al. Manual and automated office measurements in relation to awake ambulatory blood pressure monitoring.
Fam Pract 2011;28:110–117.
13. Tang H, Gong WY, Zhang QZ, et al. Prevalence, determinants, and clinical significance of masked hypertension and white-coat hypertension in patients with chronic kidney disease.
Nephrology (Carlton) 2016;21:841–850.
14. Boggia J, Silvariño R, Luzardo L, Noboa O. Significance of white-coat and masked hypertension in chronic kidney disease and end-stage renal disease.
Hypertens Res 2014;37:882–889.
15. Garimella PS, Uhlig K. Current issues in the management and monitoring of hypertension in chronic kidney disease.
Curr Opin Nephrol Hypertens 2013;22:599–606.
16. Hermida RC, Smolensky MH, Ayala DE, et al. Abnormalities in chronic kidney disease of ambulatory blood pressure 24 h patterning and normalization by bedtime hypertension chronotherapy.
Nephrol Dial Transplant 2014;29:1160–1167.
17. Gorostidi M, Sarafidis PA, de la Sierra A, et al. Spanish ABPM Registry Investigators. Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: A 5,693-patient cross-sectional analysis from Spain.
Am J Kidney Dis 2013;62:285–294.
18. Bidani AK, Griffin KA, Epstein M. Hypertension and chronic kidney disease progression: why the suboptimal outcomes?
Am J Med 2012;125:1057–1062.
19. Turner JR, Viera AJ, Shimbo D. Ambulatory blood pressure monitoring in clinical practice: a review.
Am J Med 2015;128:14–20.
20. Bloch MJ, Basile JN. UK guidelines call for routine 24-hour ambulatory blood pressure monitoring in all patients to make the diagnosis of hypertension--not ready for prime time in the United States.
J Clin Hypertens (Greenwich) 2011;13:871–872.
21. Sharman JE, Howes FS, Head GA, et al. Home blood pressure monitoring: Australian expert consensus statement.
J Hypertens 2015;33:1721–1728.
22. Myers MG, Kaczorowski J, Dawes M, Godwin M. Automated office blood pressure measurement in primary care.
Can Fam Physician 2014;60:127–132.
23. Andreadis EA, Angelopoulos ET, Agaliotis GD, Tsakanikas AP, Mousoulis GP. Why use automated office blood pressure measurements in clinical practice?
High Blood Press Cardiovasc Prev 2011;18:89–91.
24. Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Kaczorowski J. Conventional versus automated measurement of blood pressure in the office (CAMBO) trial.
Fam Pract 2012;29:376–382.
25. Myers MG, Godwin M, Dawes M, et al. Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial.
BMJ 2011;342:d286.
26. Ragazzo F, Saladini F, Palatini P. Validation of the Microlife WatchBP O3 device for clinic, home, and ambulatory blood pressure measurement, according to the International Protocol.
Blood Press Monit 2010;15:59–62.
27. Agarwal R. Implications of blood pressure measurement technique for implementation of systolic blood pressure intervention trial (SPRINT).
J Am Heart Assoc 2017;6:e004536.
28. SPRINT Research Group. Wright JT Jr, Williamson JD, et al. A Randomized trial of intensive versus standard blood-pressure control.
N Engl J Med 2015;373:2103–2116.
29. Padwal RS, Townsend RR, Trudeau L, Hamilton PG, Gelfer M. Comparison of an in-pharmacy automated blood pressure kiosk to daytime ambulatory blood pressure in hypertensive subjects.
J Am Soc Hypertens 2015;9:123–129.
30. Heinemann M, Sellick K, Rickard C, Reynolds P, McGrail M. Automated versus manual blood pressure measurement: a randomized crossover trial.
Int J Nurs Pract 2008;14:296–302.